Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
Pharmacology, Toxicology and Pharmaceutical Science
6
5%
Business, Management and Accounting
3
2%
Economics, Econometrics and Finance
3
2%
Other
15
12%
Unknown
69
55%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 137. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 October 2026.
All research outputs
#385,159
of 34,573,323 outputs
Outputs from The Lancet
#3,734
of 52,273 outputs
Outputs of similar age
#4,655
of 398,904 outputs
Outputs of similar age from The Lancet
#29
of 220 outputs
Altmetric has tracked 34,573,323 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 52,273 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 63.1. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 398,904 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 220 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.
